Effect of the SGLT2 inhibitor on basal energy expenditure in type 2 diabates mellitus

Effect of the SGLT2 inhibitor on basal energy expenditure in type 2 diabates mellitus - SGLT2 inhibitor intervention study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020923

Enrollment

100

Registered

2016-02-08

Start date

2016-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

The patient takes medicine with SGLT2 inhibitor of three months. We prescribe only Empagliflozin in this study. The dosage depends on therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: A patient with much active mass (exercise) in everyday life A patient with after the third diabetic nephropathy A patient with liver function abnormality 85 years or older

Design outcomes

Primary

Measure	Time frame
resting energy expenditure of three months after taking medicine	—

Secondary

Measure	Time frame
body weight, respiration quotient and HbA1c of three months after taking medicine	—

Countries

Japan

Contacts

Public ContactEitaro Nakashima

Chubu Rosai Hospital, Japan Labour Health and Welfare Organization DiaDiabetes & Endocrinology, Diabetes Center

eitaro@med.nagoya-u.ac.jp052-652-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026